ELGX Insider Trading Activity and SEC Form 4 Filings
ELGX insider trading summary
No open-market insider purchases or sales of Endologix Inc (ELGX) have been reported on SEC Form 4 in the past 12 months.
Latest ELGX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 4, 2020 | Dan Lemaitre | Director | Sell | $810 (15,553 @ $0.05) |
| Sep 4, 2020 | Dan Lemaitre | Director | Sell | $2K (33,709 @ $0.05) |
| Sep 4, 2020 | Dan Lemaitre | Director | Sell | $129 (2,582 @ $0.05) |
| Aug 14, 2020 | Dan Lemaitre | Director | Sell | $92 (1,127 @ $0.08) |
| Aug 13, 2020 | Dan Lemaitre | Director | Sell | $98 (1,126 @ $0.09) |
| Aug 12, 2020 | Matthew Thompson | Chief Medical Officer | Sell | $2K (21,888 @ $0.09) |
| Aug 12, 2020 | Gregory D Waller | Director | Sell | $2K (28,630 @ $0.08) |
| Aug 12, 2020 | John Onopchenko | CEO and Director | Sell | $51K (57,415 @ $0.88) |
| Aug 12, 2020 | Timothy Nicholas Brady | Controller and Corp Secretary | Sell | $10 (113 @ $0.09) |
| Aug 12, 2020 | Thomas Wilder | Director | Sell | $1K (12,088 @ $0.08) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.